file,ref_number,ref_text,doi,doi_url,titleDoi,firstAuthDoi,author_similarity,title_similarity
experiments/gene_essentiality_cancer/ai_messages/high_complexity--IL17F,[1],"Gaffen SL, Jain R, Garg AV, Cua DJ. 2014. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nature Reviews Immunology.",10.1038/nri3707,https://doi.org/10.1038/nri3707,The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing,Gaffen,100,100
experiments/gene_essentiality_cancer/ai_messages/high_complexity--IL17F,[2],"Iwakura Y, Ishigame H, Saijo S, Nakae S. 2011. Functional specialization of interleukin-17 family members. Immunity.",10.1016/j.immuni.2011.02.012,https://doi.org/10.1016/j.immuni.2011.02.012,Functional Specialization of Interleukin-17 Family Members,Iwakura,100,100
experiments/gene_essentiality_cancer/ai_messages/high_complexity--IL17F,[3],"Wu X, Yang T, Liu X, Guo JN, Xie T, Ding Y, Lin M, Yang H. 2013. IL-17 promotes tumor angiogenesis through Stat3 pathway mediated upregulation of VEGF in gastric cancer. Tumour Biology.",10.1007/s13277-015-4372-4,https://doi.org/10.1007/s13277-015-4372-4,IL-17 promotes tumor angiogenesis through Stat3 pathway mediated upregulation of VEGF in gastric cancer,Wu,100,100
experiments/gene_essentiality_cancer/ai_messages/high_complexity--IL17F,[4],"Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E. 2002. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood.",10.1182/blood.v99.6.2114,https://doi.org/10.1182/blood.v99.6.2114,Interleukin-17 inhibits tumor cell growth by means of a T-cell–dependent mechanism,Benchetrit,100,100
